Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK Form 6-K furnishing corporate disclosures contemporaneous with the Concert Pharmaceuticals deuterium-modified drug alliance announcement.
Chemistry World quoted Concert CEO Roger Tung calling deuterium chemistry potentially analogous to 'what happened with fluorine in the 1950s' and framing…
MedCity News framed the program advancement as a needed boost for GSK's HIV pipeline given Combivir generic erosion and an FDA clinical hold on another…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Strategic alliance for deuterium-modified medicines: $35M upfront incl. $16.7M equity; CTP-518 (HIV PI), preclinical CKD compound, 3rd program. Source: GSK press, Concert filings.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Concert Pharmaceuticals, Inc. (this deal) | 2009 | $35M | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2009 deals · GlaxoSmithKline plc deals